Abstract: Conventional injectable formulations of Diclofenac are known to have excipients which cause irritation at the site of injection and are painful. Further, such conventional formulations also cause thrombophlebitis. Other injectable formulations of Diclofenac known in the prior art also contain excipients which are tissue irritants and may cause toxicity when administered through intravenous route. The cyclodextrin compounds used in Dyloject® may cause problems while elimination in the renal compromised patients. The present invention therefore provides injectable Diclofenac formulations which do not cause irritation and pain at the site of injection. Further, the formulations of the present invention do not include cyclodextrins, therefore can also be administered to the renal compromised patients.

Abstract: Edaravone, in the United States, is approved in the form of ready-to-use intravenous solution for infusion, RADICAVA. RADICAVA injection is supplied in a polypropylene bag overwrapped with polyvinyl alcohol (PVA) secondary packaging. Edaravone is susceptible to oxidation and the overwrapped package also contains an oxygen absorber and oxygen indicator to minimize oxidation. Various efforts have been put in the art for packaging edaravone drug solution in different types of packaging materials, for example, plastic containers and glass bottles to prevent edaravone from oxidation and other degradation. The present invention involves use of simple and economic container-closure system for packaging edaravone drug solution while maintaining its stability during storage, transportation and use which includes glass bottles or vials and closures made of elastic polymer or rubber (for example elastomer, isoprene rubber or butyl rubber and the like).

Abstract: Pre-mixed, ready-to-use injectable compositions possess certain advantages such as convenience and ease of use as compared to an ampule formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations. Pre-mixed, ready-to-use Vancomycin injectable preparations though marketed have numbers of disadvantages which makes its handling and use difficult. The present invention therefore provides pre-mixed, ready-to-use injectable formulations of Vancomycin which eliminates disadvantages and difficulties of the marketed product and at the same time maintains desired stability for prolonged time.